Dementia in Down syndrome: Are we ready for a clinical trial?

down_syndrome_shutterstock_76649257-2

Leen Vereenooghe summarises the TOP-COG study (Towards Onset Prevention of COGnitive decline in adults with Down syndrome). This pilot RCT highlights the need to educate people with learning disabilities and their carers about the importance of research participation.

[read the full story...]

Statins for dementia prevention: well-tolerated, but Cochrane highlight lack of evidence

14799938159_ad8a4fdd8a_k

Rosalyn Nelson summarises a recently updated Cochrane systematic review of statins for dementia prevention, which finds no evidence to support their use.

[read the full story...]

Gingivitis: anti-inflammatory agents may be beneficial suggests review

shutterstock_129331370

A new review of anti-inflammatory agents for the management of gingivitis identified 14 studies. While the various anti-inflammatory agents showed benefit, the majority of the studies were at high risk of bias, so the results should be treated with caution.

[read the full story...]

Medication in advanced dementia: how can we judge what is appropriate?

shutterstock_219711667

Caroline Struthers appraises a recent US cross-sectional study of the use of medications of “questionable benefit” in nursing home residents with advanced dementia. She concludes that all medications are of questionable value if they have side effects which might have a negative impact on quality of life or are likely to cause harm.

[read the full story...]

Statins have no beneficial effect on cognition in dementia, but can cause serious side-effects

shutterstock_158586293

This updated Cochrane review on statins for the treatment of dementia contains worrying adverse effects data, but Caroline Struthers has to do a significant amount of digging to root it all out.

[read the full story...]

Do interventions proven to improve cardiovascular disease outcomes work for individuals with severe mental illness?

shutterstock_high blood pressure

Individuals with severe mental illness (SMI) have shortened life expectancies compared to the general population. This is partly down to higher rates of chronic physical illness. Cardiovascular disease (CVD) is the leading cause of death among patients using mental health services. It is assumed that interventions used to reduce CVD are similarly effective in patients with [read the full story…]

Statins do not slow down the decline of Alzheimer’s disease, says randomised controlled trial

iStock_000014809551XSmall

Previous studies have suggested that statin therapy might be a useful treatment for Alzheimer’s disease. This randomised controlled trial conducted by a team of researchers from Mount Sinai School of Medicine set out to determine if the lipid-lowering agent simvastatin slows the progression of symptoms in Alzheimer’s disease. They recruited 406 people with mild to moderate Alzheimer’s [read the full story…]